Pain and rheumatology: Thinking outside the joint by Clauw, Daniel J. & Witter, James
ARTHRITIS & RHEUMATISM
Vol. 60, No. 2, February 2009, pp 321–324
DOI 10.1002/art.24326
© 2009, American College of Rheumatology
EDITORIAL
Pain and Rheumatology: Thinking Outside the Joint
Daniel J. Clauw1 and James Witter2
Osteoarthritis (OA) of the hip and knee is a
common chronic pain condition, the impact of which will
continue to increase as the population ages. OA is
typically diagnosed when an individual presents for
medical attention with pain in the hip or knee and a
radiograph is obtained that documents degenerative
changes consistent with OA. Pain in OA has been
classically attributed to joint damage, and nearly all
therapies have been aimed at treating or curing the pain
derived from this “organ,” including exercise, topical
analgesics, oral nonsteroidal antiinflammatory drugs
(NSAIDs) and opioids, direct injections, and eventually
joint replacement.
Clearly, the limited or short-term efficacy of most
available therapies (1) and the observation that even
replacing the joint does not always cure the pain (2)
suggest that factors other than joint pathology must be
partially responsible for the pain and dysfunction expe-
rienced by patients with chronic OA pain. If damage to
the cartilage and bone is the “disease” called OA, then
the magnitude of damage to or inflammation in one or
both of these structures should predict clinical symp-
toms. However, population-based studies suggest that
there is a significant disparity between the degree of
peripheral damage noted on radiographs and the pain
and functional limitations that patients with this condi-
tion experience. The most dramatic evidence of this is
that 30–60% of individuals with moderate to severe
radiographic changes of OA are completely asymptom-
atic, and 10% of individuals with moderate to severe
knee pain have normal radiographs (3,4).
Not surprisingly, the disparity between radio-
graphic features and symptoms has led investigators to
explore the notion that psychological factors are respon-
sible for this discordance. Again, these studies have
suggested that psychological factors such as anxiety and
depression do account for some of this variance in pain
and other symptoms, but to only a small degree (5,6).
In this issue of Arthritis & Rheumatism, van Meurs
and colleagues explore a new line of research in hip OA
that suggests that some of the variance between pain and
peripheral damage can be accounted for by a gene
involved in modulating pain sensitivity, as well as several
other traits. They showed that in a large OA database in
which there was the typical poor overall relationship
between radiographic changes and pain levels, individu-
als with the 158Met variant of COMT had an almost
3-fold higher risk (P  0.02) of hip pain as compared
with carriers of the Val/Val genotype. As noted by van
Meurs et al, this effect was fully driven by the female
carriers. Female carriers of the 158Val allele were
4.9-fold more likely to have pain (95% confidence
interval 1.6–14.8, P  0.005), while radiographic damage
to the hip was present in both genotype groups.
Although this effect is very strong, it is not
surprising to those involved in the study of pain. Pain is
ultimately experienced in the brain, not in the peripheral
tissues, and the function of pain processing systems
throughout the body markedly influences who has pain
and how much pain an individual experiences. Just as we
know that there is tremendous variability in pain sensi-
tivity between strains of rodents, there similarly is great
variability in pain sensitivity among humans (7). In the
past decade, there has been an explosion of knowledge
regarding the genetics of pain. Within the past few years
alone, we have learned that genes such as those respon-
sible for catechol-O-methyltranferase (COMT), GTP
cyclohydrolase 1 (GCH1), and the voltage-gated sodium
channel Nav1.9 exert significant control in human pain
perception (8–11). Because of this, many investigators
involved in the study of pain now believe that chronic
pain is itself a disease, and the location of the body
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where it arises may not be as relevant as an individual’s
genetically determined pain sensitivity, combined with
neuroplastic changes that can occur in the central ner-
vous system (CNS) that lead to augmented pain trans-
mission.
These heightened states of pain sensitivity are
termed hyperalgesia (increased pain in response to
normally painful stimuli) and/or allodynia (pain in re-
sponse to normally nonpainful stimuli). These states
often can be triggered by an initial peripheral injury or
inflammatory process and may be regional or wide-
spread. These phenomena have been noted to occur in
nearly all individuals with conditions such as fibromyal-
gia and subsets of individuals with numerous other
chronic pain conditions, such as OA, idiopathic low back
pain, and rheumatoid arthritis (12–15). Hyperalgesia
and allodynia are not just noted by patient self-report:
their existence has been repeatedly corroborated by
functional neuroimaging studies demonstrating objec-
tive evidence of this increased pain sensitivity (15,16).
The COMT story is worth expanding upon be-
cause of its clear relevance to human pain perception.
Zubieta et al first showed that the COMT Val158Met
polymorphism was responsible for differential pain sen-
sitivity in humans, working in part by modulating the
endogenous -opioid system (17). The same Val158Met
polymorphism is weakly associated with several psychi-
atric disorders (18). Recently, Diatchenko and col-
leagues at the University of North Carolina carried out
a series of elegant studies that used haplotype analyses
to identify 3 subsets of individuals based on the findings
in 4 COMT single-nucleotide polymorphisms (SNPs),
termed low pain sensitive (LPS), average pain sensitive
(APS), and high pain sensitive (HPS) groups (10). Those
investigators have gone on to show that these subgroups
are highly predictive of pain sensitivity in a variety of
different experimental pain-inducing tasks (19). More-
over, in a prospective study, they showed that when
240 pain-free individuals were phenotyped at baseline
and then followed up for 3 years to determine in whom
temporomandibular joint (TMJ) disorder would de-
velop, individuals in the HPS group were 3 times as
likely as the others to develop TMJ disorder (10).
Similarly, their studies in rodents showed that the LPS
haplotype produced much higher levels of COMT enzy-
matic activity when compared with the APS or HPS
haplotype, and that inhibition of COMT resulted in a
profound increase in pain sensitivity in these animals.
Finally, they showed that when these synonymously
coding SNPs (which heretofore would have been con-
sidered “junk” SNPs) were combined into haplotypes,
each led to a different RNA structure with markedly
different activity (20).
The differential effect of COMT in male and
female patients noted by van Meurs et al is also not
surprising given what is known about COMT. COMT is
inducible by estrogen and has been shown to be partly
responsible for sex differences in several different “phe-
notypic” characteristics of women and men, including
pain sensitivity (21). Because these types of genetic
factors may play a strong role in determining an individ-
ual’s experience with pain, it is equally as likely that
genetic and epigenetic factors also play key roles in
patient-reported outcomes in most rheumatic diseases
and may help account for sex differences noted in many
rheumatologic disorders.
The findings regarding COMT reported by van
Meurs et al are not the only data that suggest that
catecholaminergic function might be important in lead-
ing to the pain of OA. Clinical trials have shown that
classes of drugs that are thought to be acting in part via
catecholaminergic mechanisms, such as tricyclics as well
as serotonin/norepineprine reuptake inhibitors, can be
effective in treating OA as well as a number of other
chronic musculoskeletal pain syndromes (22,23). The
postulated mechanism of action of these drugs is that
they increase serotonergic/noradrenergic activity in de-
scending analgesic pathways. Attenuated descending
analgesic activity, which is but one potential mechanism
for the hyperalgesia/allodynia seen in patients with
chronic pain states, has been noted in many chronic pain
syndromes including OA (14,24). The effect sizes and
the overall safety profile of these CNS-acting drugs may
actually be superior to those seen with more commonly
used treatments for OA such as NSAIDs, yet we rarely
consider using these medications when treating OA or
other musculoskeletal pain syndromes.
OA is not likely to be the only rheumatologic
disorder in which the discordance between peripheral
inflammation and/or damage might be attributable to
“central” factors. In systemic lupus erythematosus
(SLE), for example, neither the degree of inflammation
nor the degree of damage is highly associated with pain,
fatigue, function, or other symptoms of SLE (25–27).
Instead, the presence or absence of comorbid fibromy-
algia (which occurs in 20% of patients with SLE as well
as those with other autoimmune disorders) is the largest
predictor of pain, fatigue, and function in patients with
SLE (28,29). In fact, Wolfe and Rasker (30) have shown
that across all rheumatic diseases, the symptom intensity
scale score is a potent predictor of functional status and
pain severity regardless of the underlying rheumatologic
322 EDITORIAL
disorder. Furthermore, these scores are associated with
more severe medical illness, greater mortality, and in-
creased sociodemographic disadvantage (30). The symp-
tom intensity score is likely a simple measure of the pain
and/or sensory amplification that can occur in isolation
(e.g., fibromyalgia) or accompanying any chronic pain
state, and we are now beginning to understand the
“neurobiology” of sensory systems.
Thus, it is time for us to begin to “think outside
the joint” when it comes to pain in rheumatic diseases.
Within our field, we continue to focus most of our
research and clinical efforts on the peripheral structures,
even though these factors are, at best, modest predictors
of pain and functional disability across all rheumatologic
disorders. In fact, there is no medical condition in which
the degree of peripheral damage or inflammation accu-
rately predicts the amount of pain an individual will
experience or how the patient will functionally respond
to that pain. Pain and other symptoms occur in the brain,
not the joint.
The tremendous advances in the science of pain
provide a wonderful opportunity for rheumatologists to
better understand our patients’ pain, which is particu-
larly important, because this is often their chief com-
plaint. It will always be important for rheumatologists
and our trainees to understand how mechanisms of
disease impact the structure of peripheral organs such as
kidneys and joints, but we also need to understand
mechanisms that might impact pain transmission and the
ultimate patient experience of pain. Rheumatologists
have an opportunity to learn and then teach clinical and
research techniques that would be likely to help bridge
the gap between inflammation and structure in the
peripheral tissues and the pain, other somatic symptoms,
and dysfunction experienced by our patients.
What the van Meurs report reminds us is that the
era of evidence-based, individualized analgesia in the
rheumatic diseases is beginning to take shape. Identify-
ing successful treatment and eventual cures for chronic
pain will require carefully designed studies that test
novel hypotheses about how genetic/epigenetic factors
interact with environmental risk factors and therapeutics
(e.g., drugs, biologic agents, devices, vaccines, nonphar-
macologic therapies) in humans and animal models.
Results of these types of studies, using state-of-the art
pain assessment tools and techniques along with biomar-
kers, will help shape the way rheumatologists are trained
and subsequently treat their patients. Team science
needs to be translated to team pain management, in
order to maximize the benefits and minimize the risks of
effective and meaningful analgesia in rheumatology,
now and in the future.
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